You are here

Hikma and Adalvo sign agreement to commercialise allergic rhinitis medication across MENA markets

Aug 27,2022 - Last updated at Aug 27,2022

Hikma Pharmaceuticals PLC. (Hikma), the multinational pharmaceutical company, announces an exclusive licensing agreement with Adalvo to commercialise a nasal spray medication used to treat an increasingly prevalent respiratory disease; allergic rhinitis (AR).

The exclusive licensing and supply agreement with Adalvo expands Hikma’s respiratory portfolio in MENA. The licensed product is a combination treatment in a single advanced delivery system that has proven efficacy and safety in treating patients with AR.

This medication will help more patients control their symptoms, with an advantage of a faster onset of action and fewer adverse effects. “Ourlatest agreement with Adalvo aligns with Hikma’s strategy of creating a well-diversified pipeline of high-value products, while further solidifying our commercial presence in MENA.

By partnering with a dynamic and progressive company like Adalvo, we are building on our ongoing commitment to offering patients access to high-quality respiratory medications that actively support their treatment journey towards better health,” said Mazen Darwazah, Hikma’s executive vice chairman and president of MENA.

141 users have voted.


Get top stories and blog posts emailed to you each day.